^
Association details:
Biomarker:PD-L1 overexpression
Cancer:Triple Negative Breast Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response

Published date:
02/02/2022
Excerpt:
We aimed to develop a new signature based on immune-related genes to predict prognosis and response to immune checkpoint inhibitors in patients with triple-negative breast cancer (TNBC)....PD-1, PD-L1, PD-L2 and CTLA4 gene expression was higher in the low-risk group, suggesting IPRS could predict the response to immune checkpoint inhibitors.
DOI:
10.2217/fon-2021-0600
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

6654 / 26 - Association PD-L1 overexpression with immune checkpoint inhibitor effect in triple-negative breast cancer

Published date:
03/15/2023
Excerpt:
...this study investigated the effect of PD-L1 overexpression on the immune checkpoint inhibitor effect in triple-negative breast cancer….Above all, it was confirmed that a high PD-L1 level enhances the antitumor effect of immune checkpoint inhibitors.